المؤلفون: Gerald T; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: Thomas.Gerald@UTSouthwestern.edu., Margulis V; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX., Meng X; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX., Bagrodia A; Department of Urology, University of California San Diego, San Diego, CA., Cole S; Division of Hematology Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX., Qin Q; Division of Hematology Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX., Call SG; Tempus Labs, Inc., Chicago, IL., Mauer E; Tempus Labs, Inc., Chicago, IL., Lotan Y; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX., Woldu SL; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.

المصدر: Urologic oncology [Urol Oncol] 2023 Mar; Vol. 41 (3), pp. 148.e17-148.e24. Date of Electronic Publication: 2023 Jan 17.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 9805460 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2496 (Electronic) Linking ISSN: 10781439 NLM ISO Abbreviation: Urol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Urinary Bladder Neoplasms*/pathology , Carcinoma, Transitional Cell*, Humans ; B7-H1 Antigen/metabolism ; Retrospective Studies ; Mutation ; Genomics ; Biomarkers, Tumor/metabolism ; Xeroderma Pigmentosum Group D Protein/genetics

المؤلفون: Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Clinical Oncology, Faculty of Medicine, Menoufia University. Shebin Al-Kom, Egypt., Huang HJ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Call SG; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Karp DD; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Fu S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Subbiah V; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Pant S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Dustin DJ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Rodon J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Janku F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.

المصدر: JCO precision oncology [JCO Precis Oncol] 2022 Jul; Vol. 6, pp. e2100512.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Circulating Tumor DNA*/genetics , Neoplasms*/genetics, Biomarkers, Tumor/genetics ; Humans ; Liquid Biopsy ; Treatment Outcome

المؤلفون: Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA., Polivka J; Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic; Department of Neurology, University Hospital Pilsen, Pilsen, Czech Republic., Huang HJ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA., Treskova I; Department of Plastic Surgery, University Hospital Pilsen, Pilsen, Czech Republic., Pivovarcikova K; Department of Pathology, University Hospital Pilsen, Pilsen, Czech Republic., Fikrle T; Department of Dermatovenerology, University Hospital Pilsen, Pilsen, Czech Republic., Woznica V; Department of Plastic Surgery, University Hospital Pilsen, Pilsen, Czech Republic., Dustin DJ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA., Call SG; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA., Pesta M; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic; Department of Biology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic., Janku F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: fjanku@me.com.

المصدر: ESMO open [ESMO Open] 2022 Feb; Vol. 7 (1), pp. 100357. Date of Electronic Publication: 2021 Dec 20.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE

مواضيع طبية MeSH: Circulating Tumor DNA*/genetics , Melanoma*/genetics , Mutation* , Proto-Oncogene Proteins B-raf*/genetics, Humans ; Polymerase Chain Reaction

المؤلفون: Lapin M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Hematology and Oncology, Stavanger University Hospital, Stavanger, Norway., Huang HJ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Chagani S; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Javle M; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Shroff RT; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.; Division of Hematology/Oncology, University of Arizona Cancer Center, Tucson, AZ., Pant S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Raina A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Madwani K; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Holley VR; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Call SG; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Dustin DJ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Lanman RB; Guardant Health, Redwood City, CA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Raymond VM; Guardant Health, Redwood City, CA., Kwong LN; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Janku F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.

المصدر: JCO precision oncology [JCO Precis Oncol] 2022 Feb; Vol. 6, pp. e2100197.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Bile Duct Neoplasms*/blood , Bile Duct Neoplasms*/drug therapy , Bile Duct Neoplasms*/enzymology , Bile Duct Neoplasms*/genetics , Cholangiocarcinoma*/blood , Cholangiocarcinoma*/drug therapy , Cholangiocarcinoma*/enzymology , Cholangiocarcinoma*/genetics , Circulating Tumor DNA*/blood , Circulating Tumor DNA*/genetics , Enzyme Inhibitors*/pharmacology , Isocitrate Dehydrogenase*/antagonists & inhibitors, Bile Ducts, Intrahepatic ; Clonal Evolution ; Humans ; Prognosis

المؤلفون: Janku F; Department of Investigational Cancer Therapeutics (Phase1 Clinical Trials Program)-Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. fjanku@me.com., Huang HJ; Department of Investigational Cancer Therapeutics (Phase1 Clinical Trials Program)-Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA., Pereira DY; Phase Scientific International Ltd, Garden Grove, CA, USA., Kobayashi M; Phase Scientific International Ltd, Garden Grove, CA, USA., Chiu CH; Phase Scientific International Ltd, Kwun Tong, Hong Kong., Call SG; Department of Investigational Cancer Therapeutics (Phase1 Clinical Trials Program)-Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA., Woodbury KT; Department of Investigational Cancer Therapeutics (Phase1 Clinical Trials Program)-Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA., Chao F; Phase Scientific International Ltd, Garden Grove, CA, USA.; Phase Scientific International Ltd, Kwun Tong, Hong Kong., Marshak DR; Phase Scientific International Ltd, Garden Grove, CA, USA.; Phase Scientific International Ltd, Kwun Tong, Hong Kong., Chiu RYT; Phase Scientific International Ltd, Garden Grove, CA, USA.; Phase Scientific International Ltd, Kwun Tong, Hong Kong.

المصدر: Scientific reports [Sci Rep] 2021 Oct 04; Vol. 11 (1), pp. 19653. Date of Electronic Publication: 2021 Oct 04.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

مواضيع طبية MeSH: Cell-Free Nucleic Acids/*isolation & purification , Circulating Tumor DNA/*isolation & purification , Liquid Biopsy/*methods , Liquid-Liquid Extraction/*methods, Biomarkers, Tumor ; Humans ; Neoplasms/diagnosis ; Neoplasms/genetics ; Sensitivity and Specificity

المؤلفون: Dumbrava EE; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Call SG; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Huang HJ; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Stuckett AL; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Madwani K; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Adat A; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Hong DS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Subbiah V; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Karp DD; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Fu S; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Naing A; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Tsimberidou AM; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Moulder SL; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Koenig KH; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Barcenas CH; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Kee BK; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Fogelman DR; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Kopetz ES; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Janku F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: fjanku@me.com.

المصدر: ESMO open [ESMO Open] 2021 Oct; Vol. 6 (5), pp. 100230. Date of Electronic Publication: 2021 Aug 31.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms* , Circulating Tumor DNA*/genetics, Biomarkers, Tumor/genetics ; Class I Phosphatidylinositol 3-Kinases/genetics ; Female ; Humans ; Mutation ; Phosphatidylinositol 3-Kinases/genetics ; Treatment Outcome

المؤلفون: Janku F; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sakamuri D; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kato S; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Huang HJ; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Call SG; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Naing A; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Holley VR; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Patel SP; Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Amaria RN; Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Falchook GS; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Sarah Cannon Research Institute at HealthONE, Presbyterian/St Luke's Medical Center, Denver, Colorado., Piha-Paul SA; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zinner RG; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; University of Kentucky Markey Cancer Center, Lexington, Kentucky., Tsimberidou AM; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hong DS; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Meric-Bernstam F; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

المصدر: Cancer [Cancer] 2021 Feb 01; Vol. 127 (3), pp. 391-402. Date of Electronic Publication: 2020 Oct 29.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Mutation*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Crizotinib/*administration & dosage , Neoplasms/*drug therapy , Proto-Oncogene Proteins B-raf/*genetics , Sorafenib/*administration & dosage , Vemurafenib/*administration & dosage, Adult ; Aged ; Cell-Free Nucleic Acids/blood ; Crizotinib/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Neoplasms/genetics ; Sorafenib/adverse effects ; Vemurafenib/adverse effects

المؤلفون: Janku F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. fjanku@mdanderson.org., Park H; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Internal Medicine (Division of Oncology), Washington University School of Medicine, St. Louis, Missouri., Call SG; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Madwani K; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Oki Y; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Subbiah V; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hong DS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Naing A; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Velez-Bravo VM; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Barnes TG; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hagemeister FB; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Falchook GS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Karp DD; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wheler JJ; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Piha-Paul SA; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Garrido-Laguna I; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shpall EJ; Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fayad LE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Neelapu SS; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Meric-Bernstam F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kurzrock R; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fanale MA; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Nov 01; Vol. 26 (21), pp. 5579-5587. Date of Electronic Publication: 2020 Oct 14.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Everolimus/*administration & dosage , Histone Deacetylases/*genetics , Hodgkin Disease/*drug therapy , Sirolimus/*administration & dosage , TOR Serine-Threonine Kinases/*genetics , Vorinostat/*administration & dosage, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols ; Brentuximab Vedotin/administration & dosage ; Dose-Response Relationship, Drug ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Drug-Related Side Effects and Adverse Reactions/pathology ; Everolimus/adverse effects ; Female ; Hematopoietic Stem Cell Transplantation ; Histone Deacetylase Inhibitors/administration & dosage ; Histone Deacetylase Inhibitors/adverse effects ; Humans ; Male ; Middle Aged ; Recurrence ; Sirolimus/adverse effects ; Stem Cell Transplantation ; TOR Serine-Threonine Kinases/antagonists & inhibitors ; Vorinostat/adverse effects ; Young Adult

المؤلفون: Call SG; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA.; Molecular and Cellular Biology PhD Program, Baylor College of Medicine, Houston, TX, 77030, USA., Duren RP; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA.; Integrative Molecular and Biomedical Sciences PhD Program, Baylor College of Medicine, Houston, TX, 77030, USA., Panigrahi AK; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA., Nguyen L; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA., Freire PR; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA.; Molecular and Cellular Biology PhD Program, Baylor College of Medicine, Houston, TX, 77030, USA., Grimm SL; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, 77030, USA.; Center for Precision Environmental Health, Baylor College of Medicine, Houston, TX, 77030, USA., Coarfa C; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, 77030, USA.; Center for Precision Environmental Health, Baylor College of Medicine, Houston, TX, 77030, USA., Conneely OM; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA. orlac@bcm.edu.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, 77030, USA. orlac@bcm.edu.

المصدر: Scientific reports [Sci Rep] 2020 Feb 18; Vol. 10 (1), pp. 2851. Date of Electronic Publication: 2020 Feb 18.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

مواضيع طبية MeSH: Enhancer Elements, Genetic/*genetics , Leukemia, Myeloid, Acute/*drug therapy , Nuclear Receptor Subfamily 4, Group A, Member 1/*genetics , Proto-Oncogene Proteins c-myc/*genetics, Animals ; Cell Cycle Proteins/genetics ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cellular Reprogramming/genetics ; Dihydroergotamine/pharmacology ; E1A-Associated p300 Protein/genetics ; Epigenesis, Genetic/genetics ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/pathology ; Mice ; Nuclear Receptor Subfamily 4, Group A, Member 1/agonists ; Oncogenes/genetics ; Signal Transduction/drug effects ; Transcription Factors/genetics ; Xenograft Model Antitumor Assays

المؤلفون: Boudreaux SP; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA.; Program in Integrative Molecular and Biomedical Sciences, Baylor College of Medicine, Houston, TX, 77030, USA.; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA, 70560, USA., Duren RP; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA.; Program in Integrative Molecular and Biomedical Sciences, Baylor College of Medicine, Houston, TX, 77030, USA., Call SG; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA., Nguyen L; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA., Freire PR; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA., Narayanan P; Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX, 77030, USA., Redell MS; Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX, 77030, USA., Conneely OM; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA. orlac@bcm.edu.

المصدر: Leukemia [Leukemia] 2019 Jan; Vol. 33 (1), pp. 52-63. Date of Electronic Publication: 2018 Jun 08.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

مواضيع طبية MeSH: Dihydroergotamine/*pharmacology , Drug Delivery Systems/*methods , Gene Expression Regulation, Neoplastic/*drug effects , Leukemia, Myeloid, Acute/*drug therapy , Nuclear Receptor Subfamily 4, Group A, Member 1/*metabolism , Vasoconstrictor Agents/*pharmacology, Animals ; Apoptosis ; Cell Proliferation ; Epigenesis, Genetic ; Female ; Humans ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/metabolism ; Leukemia, Myeloid, Acute/pathology ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Nuclear Receptor Subfamily 4, Group A, Member 1/genetics ; Transcriptome ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays